Literature DB >> 10073988

Possible induction of renal dysfunction in patients with lecithin:cholesterol acyltransferase deficiency by oxidized phosphatidylcholine in glomeruli.

S Jimi1, N Uesugi, K Saku, H Itabe, B Zhang, K Arakawa, S Takebayashi.   

Abstract

To clarify the causes of renal dysfunction in familial lecithin:cholesterol acyltransferase (LCAT) deficiency, kidney samples from 4 patients with LCAT deficiency (3 homozygotes and 1 heterozygote) were examined immunohistochemically. All of the patients exhibited corneal opacities, anemia, renal dysfunction, deficiencies in plasma high density lipoprotein and LCAT activity and mass, and an increase in the ratio of plasma unesterified cholesterol to esterified cholesterol. Renal lesions began with the deposition of lipidlike structures in the glomerular basement membrane, and these structures accumulated in the mesangium and capillary subendothelium. By electron microscopy, 2 types of distinctive structure were found in glomerular lesions: vacuole structures and cross-striated, membranelike structures. The plasma oxidized phosphatidylcholine (oxPC) -modified low density lipoprotein (LDL) levels in LCAT-deficient subjects were significantly (P<0.01) higher than those in controls (1.30+/-0.82 versus 0.42+/-0.32 ng/5 microg LDL, respectively), and a significant (P<0.01) difference was observed even after adjustment for confounding factors by an analysis of covariance. The patient with the highest plasma oxPC-modified LDL had the most membranelike structures in the glomeruli and showed the greatest renal deterioration from a young age. In glomerular lesions, although there was an abundance of apoB and apoE, oil red O-positive lipids, macrophages, apoA1, and malondialdehyde were scarce. OxPC was found extracellularly in glomerular lesions, and although its distribution differed from that of apolipoproteins, it was quite similar to that of phospholipids. In conclusion, these results indicate that oxPC in plasma and glomeruli is distinctive for patients with LCAT deficiency. Therefore, oxPC may be a factor in the deterioration of kidneys in patients with familial LCAT deficiency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073988     DOI: 10.1161/01.atv.19.3.794

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  17 in total

1.  Serum metabolomic profiles from patients with acute kidney injury: a pilot study.

Authors:  Jinchun Sun; Melissa Shannon; Yosuke Ando; Laura K Schnackenberg; Nasim A Khan; Didier Portilla; Richard D Beger
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-03-06       Impact factor: 3.205

2.  DESI-MSI and METASPACE indicates lipid abnormalities and altered mitochondrial membrane components in diabetic renal proximal tubules.

Authors:  Guanshi Zhang; Jialing Zhang; Rachel J DeHoog; Subramaniam Pennathur; Christopher R Anderton; Manjeri A Venkatachalam; Theodore Alexandrov; Livia S Eberlin; Kumar Sharma
Journal:  Metabolomics       Date:  2020-01-10       Impact factor: 4.290

Review 3.  Lipid biology of the podocyte--new perspectives offer new opportunities.

Authors:  Alessia Fornoni; Sandra Merscher; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2014-05-27       Impact factor: 28.314

4.  Sex dimorphism in serum lecithin: cholesterol acyltransferase and lipoprotein lipase activities in adult sickle cell anaemia patients with proteinuria.

Authors:  M A Emokpae; O H Uwumarongie; H B Osadolor
Journal:  Indian J Clin Biochem       Date:  2010-12-29

5.  Lipid oxidation in carriers of lecithin:cholesterol acyltransferase gene mutations.

Authors:  Adriaan G Holleboom; Georgios Daniil; Xiaoming Fu; Renliang Zhang; G Kees Hovingh; Alinda W Schimmel; John J P Kastelein; Erik S G Stroes; Joseph L Witztum; Barbara A Hutten; Sotirios Tsimikas; Stanley L Hazen; Angeliki Chroni; Jan Albert Kuivenhoven
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-27       Impact factor: 8.311

Review 6.  Homozygous lecithin:cholesterol acyltransferase (LCAT) deficiency due to a new loss of function mutation and review of the literature.

Authors:  Bijan Roshan; Om P Ganda; Ranil Desilva; Rose B Ganim; Edmund Ward; Sarah D Haessler; Eliana Y Polisecki; Bela F Asztalos; Ernst J Schaefer
Journal:  J Clin Lipidol       Date:  2011-08-23       Impact factor: 4.766

7.  Corticosteroid treatment of kidney disease in a patient with familial lecithin-cholesterol acyltransferase deficiency.

Authors:  Przemysław Miarka; Barbara Idzior-Waluś; Marek Kuźniewski; Małgorzata Waluś-Miarka; Tomasz Klupa; Władysław Sułowicz
Journal:  Clin Exp Nephrol       Date:  2011-02-16       Impact factor: 2.801

8.  The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome.

Authors:  Brent Lee Lechner; Detlef Bockenhauer; Sandra Iragorri; Thomas Lyle Kennedy; Norman Joseph Siegel
Journal:  Pediatr Nephrol       Date:  2004-04-15       Impact factor: 3.714

Review 9.  Lipoprotein metabolism in chronic renal insufficiency.

Authors:  Jeffrey M Saland; Henry N Ginsberg
Journal:  Pediatr Nephrol       Date:  2007-03-28       Impact factor: 3.714

10.  Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.

Authors:  Alla Mitrofanova; Judith Molina; Javier Varona Santos; Johanna Guzman; Ximena A Morales; G Michelle Ducasa; Jonathan Bryn; Alexis Sloan; Ion Volosenco; Jin-Ju Kim; Mengyuan Ge; Shamroop K Mallela; Matthias Kretzler; Sean Eddy; Sebastian Martini; Patricia Wahl; Santiago Pastori; Armando J Mendez; George W Burke; Sandra Merscher; Alessia Fornoni
Journal:  Kidney Int       Date:  2018-10-06       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.